RT Journal Article
T1 Serum microRNAs targeting ACE2 and RAB14 genes distinguish asymptomatic from critical COVID-19 patients.
A1 Calderon-Dominguez, Maria
A1 Trejo-Gutierrez, Eva
A1 Gonzalez-Rovira, Almudena
A1 Beltran-Camacho, Lucia
A1 Rojas-Torres, Marta
A1 Eslava-Alcon, Sara
A1 Sanchez-Morillo, Daniel
A1 Calderon-Dominguez, Juan
A1 Martinez-Nicolas, Mª Pilar
A1 Gonzalez-Beitia, Estibaliz
A1 Nieto-Martin, Mª Dolores
A1 Trujillo-Soto, Teresa
A1 Rodriguez-Iglesias, Manuel A
A1 Moreno, Juan A
A1 Moreno-Luna, Rafael
A1 Duran-Ruiz, Mª Carmen
K1 ACE2
K1 COVID-19
K1 MT: Non-coding RNAs
K1 RAB14
K1 TMPRSS2
K1 Biomarkers
K1 In silico analysis
K1 MiRNA
AB Despite the extraordinary advances achieved to beat COVID-19 disease, many questions remain unsolved, including the mechanisms of action of SARS-CoV-2 and which factors determine why individuals respond so differently to the viral infection. Herein, we performed an in silico analysis to identify host microRNA targeting ACE2, TMPRSS2, and/or RAB14, all genes known to participate in viral entry and replication. Next, the levels of six microRNA candidates previously linked to viral and respiratory-related pathologies were measured in the serum of COVID-19-negative controls (n = 16), IgG-positive COVID-19 asymptomatic individuals (n = 16), and critical COVID-19 patients (n = 17). Four of the peripheral microRNAs analyzed (hsa-miR-32-5p, hsa-miR-98-3p, hsa-miR-423-3p, and hsa-miR-1246) were upregulated in COVID-19 critical patients compared with COVID-19-negative controls. Moreover, hsa-miR-32-5p and hsa-miR-1246 levels were also altered in critical versus asymptomatic individuals. Furthermore, these microRNA target genes were related to viral infection, inflammatory response, and coagulation-related processes. In conclusion, SARS-CoV-2 promotes the alteration of microRNAs targeting the expression of key proteins for viral entry and replication, and these changes are associated with disease severity. The microRNAs identified could be taken as potential biomarkers of COVID-19 progression as well as candidates for future therapeutic approaches against this disease.
PB Cell Press
SN 2162-2531
YR 2022
FD 2022-06-05
LK http://hdl.handle.net/10668/22462
UL http://hdl.handle.net/10668/22462
LA en
NO Calderon-Dominguez M, Trejo-Gutierrez E, González-Rovira A, Beltrán-Camacho L, Rojas-Torres M, Eslava-Alcón S, et al. Serum microRNAs targeting ACE2 and RAB14 genes distinguish asymptomatic from critical COVID-19 patients. Mol Ther Nucleic Acids. 2022 Sep 13;29:76-87
DS RISalud
RD Apr 5, 2025